The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease.
about
Catecholamines and cognition after traumatic brain injuryNeuroprotective Transcription Factors in Animal Models of Parkinson DiseaseA constraint-based modelling approach to metabolic dysfunction in Parkinson's diseaseΑlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's DiseaseMorphological changes of glutamatergic synapses in animal models of Parkinson's diseaseModeling intracellular signaling underlying striatal function in health and diseaseAgeing and Parkinson's disease: why is advancing age the biggest risk factor?Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseProgressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's diseasePINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease.Parkinson Disease: An Evolutionary PerspectiveParkin mutations reduce the complexity of neuronal processes in iPSC-derived human neuronsMetacognition in Early Phase Psychosis: Toward Understanding Neural Substrates.Forgetting in Reinforcement Learning Links Sustained Dopamine Signals to Motivation.Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease ModelingAssociation of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese.Cable energy function of cortical axonsDifferential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine?Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins.Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic InterneuronsCombined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.Inhibition of the mitochondrial calcium uniporter rescues dopaminergic neurons in pink1-/- zebrafish.Impaired intracellular trafficking defines early Parkinson's diseaseThe "addicted" spine.Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder.Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesisReview: Parkinson's disease: from synaptic loss to connectome dysfunction.Ventricular fibrillation cardiac arrest produces a chronic striatal hyperdopaminergic state that is worsened by methylphenidate treatment.Striatal dopamine ramping may indicate flexible reinforcement learning with forgetting in the cortico-basal ganglia circuits.Mitochondrial control of cell bioenergetics in Parkinson's disease.PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity.Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.Implications of cellular models of dopamine neurons for disease.Calcium and Parkinson's disease.Microtubule Destabilization Paves the Way to Parkinson's Disease.Selective neuronal vulnerability in Parkinson disease.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.
P2860
Q26743582-D9655806-6CF0-4FB3-B66D-DED52EAE00C6Q26765693-2DCDABFF-BE43-4E0E-90C7-0AF02EB82D91Q26778643-3A54BA78-51F3-4B34-B397-FA6C13BDD60BQ26778937-3A5ED62B-4FCA-4018-9CF1-0E2CA7200119Q26781619-E484FA93-3B71-4774-92F3-5BB0940E4BFAQ26851389-8E68A5D9-36CA-4BE4-9D97-21BF5E4DCADBQ27021628-734BD39D-D59D-44E3-8B55-B1E04A9C5C80Q27322513-34E53E0C-C575-4ABE-9088-72CC34BD8F47Q28074143-75136768-2B09-4020-9447-8373A81E1C03Q30833636-3E49E340-9C49-4617-8C18-EE2218C4FC0BQ33619324-ADC813D1-CA7A-401E-9889-78A0FD0602E0Q33619405-45B0817A-4A9F-4056-8BE5-27A85AC0D640Q35600964-B2C94301-9191-42DF-AD69-7DF9FCBCAADFQ35902420-D6129EEA-2E1C-4D6A-9887-D37EB2A61ED5Q36162490-ACA7B2CC-4E29-4EE8-AB20-1DA579B09840Q36206092-21F398DB-BC44-4044-8DBC-8D2BB75364D8Q36217232-AE9BF4F1-E98A-4777-946B-83D8482D168DQ37112858-20312452-3099-41A9-8699-C2E1B32AF80DQ37185190-0A247895-978E-4668-A932-9BF144E825C9Q37272000-70340009-9AA1-4E24-87FE-4BDD58A2B4E7Q37344220-5E6E2FE4-541C-4A25-8B35-8F0910DA9EA2Q37591146-3B135D34-C5B1-435C-B4EE-906A88B2E9CFQ37664178-BC880E26-E34E-400F-BE35-CEAF75E5CD1EQ38256380-528DF015-B535-46CC-AC71-89AD3C3DC9ADQ38261007-7596CB73-9396-4373-923C-30C54FCD9AC0Q38310102-A04C50E7-650E-4E4F-961E-D544943ED57AQ38437361-094B3C8C-6B64-44A1-875A-1D1457EEBFA3Q38605280-760850E9-F257-4794-8036-6461AB0DC8E2Q38650395-643F728F-2583-45DB-A166-22F48B6BE028Q38690582-E633C67E-AFD2-4360-A9CC-32B59B4F1E64Q38779277-52EFEBC0-189E-44CC-9DD6-0F652ED67499Q38811534-38D2ECEB-F539-44F0-BF6C-2FBE0EA48835Q38835806-C79F71BF-AF45-4A78-882D-0E920BD4D65EQ38855994-BE3385E5-06AD-4836-99AD-61881977B71EQ38943090-3BC4051B-AEEB-44EC-AF55-08E53BF2D8F3Q38945252-B0D8F529-052B-4535-A399-DAA1F9367E30Q38984991-269D2C44-3826-41A9-8B19-36611CD9BD68Q39095738-7BAD59BA-FD59-48AE-94CA-E448DB6C14B9Q39199926-BCB213FD-CD09-405E-AC30-7F81EE30FFC2Q41117800-0DAEF64B-E9FA-4AFF-89AD-D96965168355
P2860
The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The energy cost of action pote ...... bility in Parkinson's disease.
@en
The energy cost of action pote ...... bility in Parkinson's disease.
@nl
type
label
The energy cost of action pote ...... bility in Parkinson's disease.
@en
The energy cost of action pote ...... bility in Parkinson's disease.
@nl
prefLabel
The energy cost of action pote ...... bility in Parkinson's disease.
@en
The energy cost of action pote ...... bility in Parkinson's disease.
@nl
P2860
P356
P1476
The energy cost of action pote ...... bility in Parkinson's disease.
@en
P2093
Eleftheria K Pissadaki
P2860
P356
10.3389/FNCOM.2013.00013
P50
P577
2013-03-18T00:00:00Z